CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LLY

Phase 3

Development Phase

1

Upcoming Catalysts

1

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Oct '27
LLYPhase 3

Tirzepatide Phase 3 Est. Readout

Tirzepatide
Oct 2027~
CT.gov
00%
Development History
Nov '26
LLYPhase 3
✓Positive

Tirzepatide Phase 3 Est. Readout (SURPASS-T1D-2)

Tirzepatide
Nov 2026~
CT.gov
Competitive Landscape
Drug Information

Target Indication

Overweight

Clinical Trial

NCT04184622

Last updated: 12/4/2025

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

Dec 30, 2041(15y 2m)

Patents Listed

10

Exclusivity

NCENPPI-958M-82NCENP

Application

NDA 215866
Regulatory Approvals
EMA9/15/2022

Mounjaro

Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). For trial results with respect to obstructive sleep apnoea (OSA) and heart failure with preserved ejection fraction (HFpEF), see section 5.1.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.